Back to Search Start Over

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Authors :
Gockley, Allison A.
Kolin, David L.
Awtrey, Christopher S.
Lindeman, Neal I.
Matulonis, Ursula A.
Konstantinopoulos, Panagiotis A.
Source :
Gynecologic Oncology. Aug2018, Vol. 150 Issue 2, p219-226. 8p.
Publication Year :
2018

Abstract

A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
*TREATMENT of endometrial cancer
*BRCA genes
*POLY ADP ribose
*GERM cells
*TREATMENT effectiveness

Details

Language :
English
ISSN :
00908258
Volume :
150
Issue :
2
Database :
Academic Search Index
Journal :
Gynecologic Oncology
Publication Type :
Academic Journal
Accession number :
130744573
Full Text :
https://doi.org/10.1016/j.ygyno.2018.05.028
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details